Ann Lab Med.  2014 Nov;34(6):469-470. 10.3343/alm.2014.34.6.469.

A Rare Case of Polycythemia Vera Following Acute Undifferentiated Leukemia Remission

Affiliations
  • 1Department of Laboratory Medicine, Korea University Guro Hospital, Seoul, Korea. ysy5613@kumc.or.kr
  • 2Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.

Abstract

No abstract available.


MeSH Terms

Acute Disease
Aged
Bone Marrow/metabolism/pathology
Female
Humans
Janus Kinase 2/genetics
Leukemia/*complications/therapy
Mutation, Missense
Polycythemia Vera/*diagnosis/etiology
Real-Time Polymerase Chain Reaction
Remission Induction
Janus Kinase 2

Cited by  1 articles

Polycythemia vera emerging eighteen years after acute myeloid leukemia diagnosis
Stephen E. Langabeer, Derick W. O’Flynn, Mary R. Cahill
Blood Res. 2021;56(2):121-123.    doi: 10.5045/br.2021.2021040.


Reference

1. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010; 24:1574–1579. PMID: 20631743.
2. Antonioli E, Guglielmelli P, Poli G, Santini V, Bosi A, Vannucchi AM. Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. Blood. 2007; 110:4620–4621. PMID: 18056850.
3. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013; 88:507–516. PMID: 23695894.
Article
4. Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi F. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. Clin Cancer Res. 2013; 19:327–335. PMID: 23209034.
Article
5. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007; 138:354–358. PMID: 17614822.
Article
6. Jekarl DW, Han SB, Kim M, Lim J, Oh EJ, Kim Y, et al. JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. Korean J Hematol. 2010; 45:46–50. PMID: 21120162.
7. Swaminathan S, Madkaikar M, Ghosh K, Vundinti BR, Kerketta L, Gupta M. Novel immunophenotypic and morphologic presentation in acute myeloid leukemia (AML) with JAK2 V617F mutation. Eur J Haematol. 2010; 84:180–182. PMID: 19824900.
8. Belotti A, Doni E, Elli E, Rossi V, Pioltelli P, Pogliani EM. Development of polycythemia vera after chemotherapy-induced remission of acute myeloid leukemia: a case report. Acta Haematol. 2011; 126:52–53. PMID: 21454967.
Article
9. Portell CA, Sekeres MA, Rogers HJ, Tiu RV. De novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone. Br J Haematol. 2012; 157:266–267. PMID: 22150289.
10. Chabannon C, Bost M, Hollard D. A case of polycythemia vera occurring in a patient with acute non-lymphoblastic leukemia (ANLL) in long-term first complete remission. Leukemia. 1994; 8:1243–1244. PMID: 8035619.
Full Text Links
  • ALM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr